Eagle Pharmaceuticals, Inc. Accounts Receivable
Eagle Pharmaceuticals, Inc. had Accounts Receivable of $115.14 million as of 2023-06-30, per its 10-Q/A filed 2023-08-09.
Discontinued › Balance Sheet › Assets › Assets, Current › Receivables, Net, Current
us-gaap:AccountsReceivableNetCurrent · last filed 2023-08-09
- 2023-06-30: Accounts Receivable, after Allowance for Credit Loss, Current $115.14M.
- 2023-03-31: Accounts Receivable, after Allowance for Credit Loss, Current $114.95M.
- 2022-12-31: Accounts Receivable, after Allowance for Credit Loss, Current $72.44M.
- 2022-09-30: Accounts Receivable, after Allowance for Credit Loss, Current $96.93M.
| Period end | Accounts Receivable, after Allowance for Credit Loss, Current | Accounts Receivable, after Allowance for Credit Loss, Current as first filed |
|---|---|---|
| 2023-06-30 | $115.14M 10-Q/A · filed 2023-08-09 | |
| 2023-03-31 | $114.95M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $72.44M 10-Q/A · filed 2023-08-09 | |
| 2022-09-30 | $96.93M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $85.92M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $130.86M 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $41.15M 10-K · filed 2023-03-23 | |
| 2021-09-30 | $45.34M 10-Q · filed 2021-11-09 | |
| 2021-06-30 | $52.66M 10-Q · filed 2021-08-09 | |
| 2021-03-31 | $44.87M 10-Q · filed 2021-05-10 | |
| 2020-12-31 | $51.12M 10-K · filed 2022-03-08 | |
| 2020-09-30 | $52.20M 10-Q · filed 2020-11-02 | |
| 2020-06-30 | $46.78M 10-Q · filed 2020-08-10 | |
| 2020-03-31 | $54.49M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $48.00M 10-K · filed 2021-03-05 | |
| 2019-09-30 | $44.81M 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $60.34M 10-Q · filed 2019-08-08 | |
| 2019-03-31 | $63.93M 10-Q · filed 2019-05-07 | |
| 2018-12-31 | $66.49M 10-K · filed 2020-03-02 | |
| 2018-09-30 | $78.46M 10-Q · filed 2018-11-01 | |
| 2018-06-30 | $69.40M 10-Q · filed 2018-08-07 | |
| 2018-03-31 | $53.43M 10-Q · filed 2018-05-10 | |
| 2017-12-31 | $53.82M 10-K · filed 2019-02-28 | |
| 2017-09-30 | $71.60M 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $53.23M 10-Q · filed 2017-08-09 | |
| 2017-03-31 | $84.74M 10-Q · filed 2017-05-08 | |
| 2016-12-31 | $42.19M 10-K · filed 2018-02-26 | |
| 2016-09-30 | $47.05M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $52.03M 10-Q · filed 2016-08-09 | |
| 2016-03-31 | $26.53M 10-Q · filed 2016-05-10 | |
| 2015-12-31 | $26.27M 10-K · filed 2017-03-15 | |
| 2015-09-30 | $12.22M 10-Q · filed 2015-11-12 | |
| 2015-06-30 | $12.98M 10-Q · filed 2015-08-11 | |
| 2015-03-31 | $10.51M 10-Q · filed 2015-05-15 | |
| 2014-12-31 | $11.96M 10-K · filed 2016-02-29 | |
| 2014-09-30 | $7.30M 10-K · filed 2016-02-29 | |
| 2014-06-30 | $6.71M 10-Q · filed 2014-08-11 | |
| 2014-03-31 | $7.82M 10-Q · filed 2014-05-15 | |
| 2013-09-30 | $5.12M 10-K · filed 2014-12-22 | $5.12M 10-Q · filed 2014-05-15 |